Efficacy of immune checkpoint inhibitors in non-small cell lung cancer: A systematic review and meta-analysis

BACKGROUND: Immune checkpoint inhibitors (ICIs) have demonstrated remarkable efficacy in non-small cell lung cancer (NSCLC). However, only a minority of NSCLC patients benefit from ICIs, and whether the magnitude of benefit is specific factor-dependent remains unclear. We performed a systematic revi...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Fang, Wang, Yucai, Tang, Lin, Mansfield, Aaron Scott, Adjei, Alex A., Leventakos, Konstantinos, Duma, Narjust, Wei, Jia, Wang, Lifeng, Liu, Baorui, Molina, Julian R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9425065/
https://www.ncbi.nlm.nih.gov/pubmed/36052255
http://dx.doi.org/10.3389/fonc.2022.955440

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9425065/
https://www.ncbi.nlm.nih.gov/pubmed/36052255
http://dx.doi.org/10.3389/fonc.2022.955440

Ejemplares similares